ATE268174T1 - Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen - Google Patents

Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE268174T1
ATE268174T1 AT98966345T AT98966345T ATE268174T1 AT E268174 T1 ATE268174 T1 AT E268174T1 AT 98966345 T AT98966345 T AT 98966345T AT 98966345 T AT98966345 T AT 98966345T AT E268174 T1 ATE268174 T1 AT E268174T1
Authority
AT
Austria
Prior art keywords
compound
formula
sibutramin
orlistat
pharmaceutical compositions
Prior art date
Application number
AT98966345T
Other languages
English (en)
Inventor
David John Heal
Helen Christine Jackson
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE268174T1 publication Critical patent/ATE268174T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
AT98966345T 1997-12-24 1998-12-16 Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen ATE268174T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9727131.6A GB9727131D0 (en) 1997-12-24 1997-12-24 Therapeutic agents
PCT/EP1998/008249 WO1999033450A2 (en) 1997-12-24 1998-12-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
ATE268174T1 true ATE268174T1 (de) 2004-06-15

Family

ID=10824083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98966345T ATE268174T1 (de) 1997-12-24 1998-12-16 Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen

Country Status (26)

Country Link
US (1) US6403641B2 (de)
EP (1) EP1039900B1 (de)
JP (1) JP2001527036A (de)
KR (1) KR20010033531A (de)
CN (1) CN1134257C (de)
AT (1) ATE268174T1 (de)
AU (1) AU758181B2 (de)
BG (1) BG104568A (de)
BR (1) BR9814498A (de)
CA (1) CA2315259A1 (de)
CZ (1) CZ20002392A3 (de)
DE (1) DE69824313T2 (de)
DK (1) DK1039900T3 (de)
ES (1) ES2222001T3 (de)
GB (1) GB9727131D0 (de)
HK (1) HK1034446A1 (de)
HU (1) HUP0300615A3 (de)
IL (1) IL136733A (de)
NO (1) NO20003313L (de)
NZ (1) NZ505686A (de)
PL (1) PL342099A1 (de)
PT (1) PT1039900E (de)
SK (1) SK9492000A3 (de)
TR (1) TR200001869T2 (de)
UA (1) UA70310C2 (de)
WO (1) WO1999033450A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
SI1307264T1 (en) 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
WO2004110338A2 (en) * 2003-06-12 2004-12-23 Biomas Ltd. Methods of treating obesity and related disorders using tellurium and selenium compounds
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
SI3263118T1 (sl) 2004-05-10 2019-12-31 University Of Copenhagen Lanena semena za uravnavanje telesne teže
WO2009033483A1 (en) 2007-09-12 2009-03-19 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JP5738011B2 (ja) * 2011-03-04 2015-06-17 株式会社ブリヂストン 二次電池の非水電解液用添加剤、二次電池用非水電解液及び非水電解液二次電池
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
ES2222001T3 (es) 2005-01-16
AU2273899A (en) 1999-07-19
GB9727131D0 (en) 1998-02-25
IL136733A (en) 2004-08-31
DE69824313D1 (de) 2004-07-08
HUP0300615A2 (hu) 2003-07-28
US20020010160A1 (en) 2002-01-24
CN1134257C (zh) 2004-01-14
NZ505686A (en) 2002-07-26
PL342099A1 (en) 2001-05-21
SK9492000A3 (en) 2001-07-10
CZ20002392A3 (cs) 2002-01-16
BG104568A (bg) 2001-02-28
WO1999033450A3 (en) 1999-09-02
US6403641B2 (en) 2002-06-11
IL136733A0 (en) 2001-06-14
UA70310C2 (uk) 2004-10-15
BR9814498A (pt) 2000-10-10
CN1284872A (zh) 2001-02-21
PT1039900E (pt) 2004-09-30
CA2315259A1 (en) 1999-07-08
EP1039900B1 (de) 2004-06-02
KR20010033531A (ko) 2001-04-25
TR200001869T2 (tr) 2000-10-23
WO1999033450A2 (en) 1999-07-08
HUP0300615A3 (en) 2005-04-28
JP2001527036A (ja) 2001-12-25
EP1039900A2 (de) 2000-10-04
DE69824313T2 (de) 2005-08-25
NO20003313L (no) 2000-08-11
AU758181B2 (en) 2003-03-20
NO20003313D0 (no) 2000-06-23
DK1039900T3 (da) 2004-10-04
HK1034446A1 (en) 2001-10-26

Similar Documents

Publication Publication Date Title
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
FI934983A (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
DK0503440T3 (da) Sumatriptanholdige lægemidler
MX9707453A (es) Derivados de quinazolina.
SE9504661D0 (sv) New compounds
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
GEP20043324B (en) Purine Derivatives
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
SE9504662D0 (sv) New compounds
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
SE0004827D0 (sv) Therapeutic compounds
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
AP9801235A0 (en) Erythromycin derivatives.
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1039900

Country of ref document: EP

REN Ceased due to non-payment of the annual fee